{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["34(4)"],"submitter":["Ruzicka M"],"pubmed_abstract":["Retinoic acid-inducible gene-I (RIG-I) is a cytoplasmic immune receptor sensing viral RNA. It triggers the release of type I interferons (IFN) and proinflammatory cytokines inducing an adaptive cellular immune response. We investigated the therapeutic potential of systemic RIG-I activation by short 5'-triphosphate-modified RNA (ppp-RNA) for the treatment of acute myeloid leukemia (AML) in the syngeneic murine C1498 AML tumor model. ppp-RNA treatment significantly reduced tumor burden, delayed disease onset and led to complete remission including immunological memory formation in a substantial proportion of animals. Therapy-induced tumor rejection was dependent on CD4<sup>+</sup> and CD8<sup>+</sup> T cells, but not on NK or B cells, and relied on intact IFN and mitochondrial antiviral sign"],"journal":["Leukemia"],"pagination":["1017-1026"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7214254"],"repository":["biostudies-literature"],"pubmed_title":["RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade."],"pmcid":["PMC7214254"],"pubmed_authors":["Endres S","Meinl H","Boehmer DFR","Lichtenegger FS","Koenig LM","Kocheise L","Kobold S","Subklewe M","Zeitlhofler M","Ruzicka M","Vick B","Schnurr M","Ahlfeld J","Duewell P","Jeremias I","Formisano S","Heuer EM","Rothenfusser S"],"additional_accession":[]},"is_claimable":false,"name":"RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.","description":"Retinoic acid-inducible gene-I (RIG-I) is a cytoplasmic immune receptor sensing viral RNA. It triggers the release of type I interferons (IFN) and proinflammatory cytokines inducing an adaptive cellular immune response. We investigated the therapeutic potential of systemic RIG-I activation by short 5'-triphosphate-modified RNA (ppp-RNA) for the treatment of acute myeloid leukemia (AML) in the syngeneic murine C1498 AML tumor model. ppp-RNA treatment significantly reduced tumor burden, delayed disease onset and led to complete remission including immunological memory formation in a substantial proportion of animals. Therapy-induced tumor rejection was dependent on CD4<sup>+</sup> and CD8<sup>+</sup> T cells, but not on NK or B cells, and relied on intact IFN and mitochondrial antiviral sign","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-05-29T21:59:46.773Z","creation":"2025-05-29T21:59:46.773Z"},"accession":"S-EPMC7214254","cross_references":{"pubmed":["31740809"],"doi":["10.1038/s41375-019-0639-x"]}}